Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review
In real-world cohorts across Asia and South America, initiating or switching to DTG + 3TC resulted in high proportions of people achieving or maintaining virologic suppression and demonstrated a good safety profile at multiple time points, consistent with clinical trial and real-world data in North America and Europe.
Authors
- Michelle Moorhouse (ORCID: https://orcid.org/0000-0002-8410-3247)
- Chien‐Yu Cheng (ORCID: https://orcid.org/0000-0002-1886-0370)
- Adrian Yit Reen Ooi
- Andres Felipe Doblado-Maldonado (ORCID: https://orcid.org/0000-0001-5683-5603)
- Emílio Letang (ORCID: https://orcid.org/0000-0002-9970-1880)
- Bryn Jones (ORCID: https://orcid.org/0000-0001-9296-367X)
- Wei Sun
Institutions
- National Yang Ming Chiao Tung University (TW)
- ViiV Healthcare (Spain) (ES)
- University of the Witwatersrand (ZA)
- ViiV Healthcare (United Kingdom) (GB)
- Ministry of Health and Welfare (TW)
Publication Details
- Journal
- Medicine
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1097/md.0000000000043558
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- ViiV Healthcare